Article

Comparison of the Quality of Life of Type 2 Diabetes Mellitus Patients Treated with Biguanides, Thiazolidinediones and Sulphonyl ureas

Vishvas Garg1★★ Corresponding author

  1. 1Ph.D student, University of New Mexico, College of Pharmacy, Dept of Pharmacy Practice, 212 Princeton Dr.SE, Apt # B, Albequrque, NM- 87106, USA.

CORRESPONDENCE

Vishvas Garg

Ph.D student, University of New Mexico, College of Pharmacy, Dept of Pharmacy Practice, 212 Princeton Dr.SE, Apt # B, Albequrque, NM- 87106, USA.

vishvas4588@gmail.com

Received: 17-10-2011; Accepted: 05-11-2011.

Volume 5, Issue 1 · pp. 61–66 · PUBLISHED · DOI:

View on IJPP original site ↗

ABSTRACT

Currently, more than 250 million people are suffering from diabetes mellitus (DM) worldwide. The purpose of this paper was to determine and compare the impact of the drug induced adverse drug reactions (ADRs) caused by biguanides, thiazolidinediones and sulfonylureas on the Health-Related-Quality-of-Life (HRQoL) in the T2DM patients. Using PubMed MeSH terms, comprehensive drug induced ADRs profiles of biguanides, thiazolidinediones and sulfonylureas were developed, separately. Furthermore, health utility values associated with each of the ADRs were determined using literature search. Quality-Adjusted-Life-Years (QALY's) measure was used to calculate and compare the impact of drug induced ADRs on HRQoL of the patients. Overall, we found that, followed by sulfonylureas and thiazolidinediones, metformin induced ADRs cause maximum decrement in the HRQoL of T2DM patients. We further found existence of both between group and within drug group differences between the magnitudes of the impact of different drug induced ADRs on the HRQoL of patients.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Garg, V. (). Comparison of the Quality of Life of Type 2 Diabetes Mellitus Patients Treated with Biguanides, Thiazolidinediones and Sulphonyl ureas. Indian Journal of Pharmacy Practice, 5(1), 61–66.